On April 24 2026, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of Sanofi’s Cenrifki (tolebrutinib) for the treatment of secondary progressive multiple sclerosis (SPMS) in patients who have not experienced relapses. The recommendation was based on the HERCULES phase‑3 study and supporting phase‑3 trials in relapsing MS, all of which were published in the New England Journal of Medicine and presented at major neurology conferences.
The CHMP’s endorsement removes a major regulatory hurdle for Cenrifki, positioning the drug for potential entry into the EU market within the next few months. Approval would expand Sanofi’s neurology portfolio and provide a new therapeutic option for a patient group that has limited treatment choices, reinforcing the company’s focus on rare‑disease and neurology opportunities.
Sanofi’s leadership highlighted that the positive opinion is a critical step toward EU approval and that the company will continue to engage with regulators to expedite the final decision. The development aligns with Sanofi’s strategy to diversify beyond its flagship Dupixent franchise and could generate significant revenue once approved.
The positive EU opinion follows a December 2025 rejection by the U.S. Food and Drug Administration, which cited efficacy and safety concerns and concluded that a favorable benefit‑risk profile could not be established. The divergence between EU and U.S. regulatory assessments underscores the complexity of bringing Cenrifki to market and highlights the importance of the CHMP endorsement for Sanofi’s global launch strategy.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.